United States Patent 9,670,163: Ivacaftor Amorphous Solid Composition Claims and Patent Landscape
US Patent No. 9,670,163 protects amorphous solid compositions of ivacaftor, the active ingredient in Kalydeco, together with selected mixed amorphous-crystalline forms, polymer-containing dispersions, a spray-drying process, and cystic-fibrosis treatment methods.[1] The patent is assigned to Vertex Pharmaceuticals Incorporated and was issued on June 6, 2017.[1]
The principal commercial risk is a generic manufacturer producing ivacaftor in an amorphous or predominantly amorphous solid form, particularly through spray drying or polymer-based solid dispersion technology. The patent does not claim every ivacaftor product. Its scope is concentrated on solid-state form, residual crystallinity, formulation architecture, manufacturing process and use in cystic fibrosis.
What drug does US Patent 9,670,163 protect?
The claimed compound is ivacaftor, also known as VX-770. The chemical name in the claims is:
N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide.
Ivacaftor is a small-molecule CFTR potentiator. FDA approved Kalydeco on January 31, 2012, for eligible patients with cystic fibrosis carrying specified responsive CFTR mutations.[2] The patent concerns the physical form and processing of ivacaftor rather than discovery of the active pharmaceutical ingredient itself.
The user-provided claim text contains a typographical variation, "oguinoline," in claim 1. The operative chemical name is the quinoline compound used throughout the patent and in the ivacaftor identity.
What are the claims of US 9,670,163?
The claims fall into five groups: composition claims, solid-dispersion claims, method-of-treatment claims, process claims and an absolute-amorphous-form claim.
| Claim group |
Claims |
Protected subject matter |
| Mixed solid composition |
1 |
Amorphous ivacaftor with less than about 30% crystalline ivacaftor |
| Excipients |
2 |
Claim 1 composition with a pharmaceutically acceptable excipient |
| Cystic fibrosis treatment |
3 |
Administration of claim 1 composition to treat CF in a mammal |
| Solid dispersion |
4 |
Claim 2 composition formulated as a solid dispersion |
| Spray-drying process |
5 |
Mixing crystalline ivacaftor with solvent and optional polymer, then spray drying |
| Low-crystallinity composition |
6 |
Claim 1 composition with less than about 5% crystalline ivacaftor |
| Fully amorphous composition |
7 |
Composition comprising 100% amorphous ivacaftor as determined by Cu K-alpha XRPD |
| Polymer-containing composition |
8 |
Claim 1 composition containing a polymer |
The claims use nested dependency. Claims 2, 4, 6 and 8 narrow claim 1. Claim 7 is an independent composition claim directed to a fully amorphous material, while claim 5 independently targets a manufacturing route.
How broad is claim 1?
Claim 1 requires four core elements:
- A solid pharmaceutical composition.
- Amorphous ivacaftor.
- Less than about 30% crystalline ivacaftor.
- The identified ivacaftor chemical compound.
The claim does not expressly require an excipient, polymer, particular dosage form or particular manufacturing process. A tablet, capsule, powder, granule or other solid product could potentially fall within the claim if it contains the required amorphous/crystalline balance.
The phrase "less than about 30%" creates a numerical limitation with potential boundary disputes. The analysis would depend on the assay method, sampling protocol, batch variability and the meaning of "about." The patent specification and prosecution history would be important in determining whether the threshold permits measurement error around 30%.[1]
Claim 1 is broader than claim 6 because claim 6 lowers the crystalline content to less than about 5%. A product containing 4% crystalline ivacaftor may fall within both claims. A product containing 10% crystalline ivacaftor may fall within claim 1 but not claim 6, subject to the measurement method.
What does the 100% amorphous claim cover?
Claim 7 covers a solid pharmaceutical composition comprising 100% amorphous ivacaftor, determined by Cu K-alpha radiation using powder X-ray diffraction.
This claim is commercially significant because it does not require a polymer, excipient or spray-drying step on its face. A generic product containing fully amorphous ivacaftor could face claim 7 even if its formulation composition and manufacturing process differ from the patented example.
The claim's practical scope depends heavily on analytical testing. "100% amorphous" is determined through XRPD, but XRPD detection limits may not establish literal absence of every crystalline domain. A generic challenger could contest whether the method can distinguish absolute zero crystallinity from crystallinity below the instrument's detection threshold. The patent holder would likely rely on XRPD data, orthogonal solid-state testing and batch-specific evidence.
What formulations are protected by US 9,670,163?
The patent protects several formulation configurations.
Amorphous ivacaftor with excipients
Claim 2 adds a pharmaceutically acceptable excipient. This can include conventional pharmaceutical carriers, binders, fillers, disintegrants, lubricants, surfactants or other formulation materials, provided the underlying claim 1 composition is present.
The claim does not identify a particular excipient. Its broad language may reach multiple dosage forms, but the composition must retain the required amorphous and crystalline characteristics.
Polymer-based solid dispersions
Claims 4 and 8 cover polymer-containing products and solid dispersions. Polymers can improve dissolution, inhibit recrystallization or support bioavailability for poorly soluble compounds.
A product may be exposed even if its label does not identify the solid-state form. In an ANDA dispute, the patentee could obtain information through discovery, testing of commercial samples and manufacturing records.
Spray-dried products
Claim 5 requires a process comprising:
- forming a mixture containing crystalline ivacaftor and a solvent;
- optionally including a polymer; and
- spray drying the mixture to produce the solid composition.
This claim is narrower than the composition claims because it requires a specific process sequence. A generic manufacturer using hot-melt extrusion, solvent evaporation, milling, precipitation or another route may avoid literal infringement of claim 5 while still facing claims 1, 6, 7 or 8.
What is the scope of the cystic-fibrosis method claim?
Claim 3 covers treating cystic fibrosis in a mammal by administering an effective amount of the claim 1 composition.
The claim requires both:
- the specific solid composition; and
- administration for cystic fibrosis treatment.
It does not expressly limit the patient genotype, age, dose, route or treatment duration. The broad patient language could cover human CF treatment, although enforcement against a generic product would typically intersect with the approved label, ANDA certification and inducement theories.
A generic applicant may attempt a section viii label carve-out for patented uses if the approved labeling contains non-patented indications or patient populations. That strategy is less effective where the label necessarily instructs treatment of cystic fibrosis using the claimed composition.
When does US Patent 9,670,163 expire?
The reported patent expiration date is October 31, 2032, based on the patent's priority framework and the standard patent-term calculation.[3] The exact enforceable term can be affected by patent-term adjustment, terminal disclaimers, patent-term extension and regulatory exclusivity calculations.
| Event |
Date or period |
| Kalydeco FDA approval |
January 31, 2012 |
| US 9,670,163 issue |
June 6, 2017 |
| Reported patent expiration |
October 31, 2032 |
| Kalydeco five-year NME exclusivity |
Through January 31, 2017 |
| Pediatric exclusivity extension |
Six additional months where applicable |
| Orphan-drug exclusivity |
Generally seven years from approval for the protected indication |
FDA small-molecule exclusivity and patent exclusivity are separate. Kalydeco's five-year new chemical entity exclusivity has expired. Orphan-drug exclusivity also does not replace the patent term and applies only to the protected indication and patient population.[2][4]
What is the Orange Book status of Kalydeco and this patent?
Kalydeco is listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.[4] Orange Book listings can include patents directed to the drug substance, drug product, formulation or method of use.
US 9,670,163 is relevant to Kalydeco's solid-state and formulation protection. Its commercial impact depends on whether FDA lists it against the relevant Kalydeco strength and dosage form and whether the listed patent remains active for the ANDA certification period.
An Orange Book listing generally requires an ANDA applicant to submit one of four certifications:
- Paragraph I: no patent information has been submitted;
- Paragraph II: the patent has expired;
- Paragraph III: the applicant will not market until patent expiration; or
- Paragraph IV: the patent is invalid, unenforceable or will not be infringed.
The patent's formulation and composition claims create a likely Paragraph IV target for any ANDA applicant using an amorphous ivacaftor product.
Which companies are challenging the patent?
Publicly available information does not establish a confirmed, final Paragraph IV litigation outcome specifically involving US 9,670,163. The relevant challenger class is manufacturers filing ANDAs for generic ivacaftor or ivacaftor-containing products.
A Paragraph IV filing would normally trigger notice to Vertex and could produce a Hatch-Waxman action under 21 U.S.C. § 355(j)(5)(B)(iii). A timely patent suit generally triggers a 30-month stay of ANDA approval, subject to statutory exceptions and court action.[5]
The most plausible attack positions are:
| Challenge |
Potential argument |
| Anticipation |
Earlier disclosure of amorphous ivacaftor or a composition below the claimed crystallinity threshold |
| Obviousness |
Routine conversion of crystalline ivacaftor into an amorphous dispersion using known pharmaceutical methods |
| Written description |
Insufficient support for the breadth of "less than about 30%" or "100% amorphous" |
| Enablement |
Inability to make the full range of covered compositions without undue experimentation |
| Indefiniteness |
Ambiguity in "about," "100% amorphous" or XRPD measurement |
| Noninfringement |
Product contains more than 30% crystalline material or uses a non-covered form |
| Process avoidance |
Manufacturing does not use the claimed solvent and spray-drying sequence |
How strong is the patent estate for ivacaftor?
The ivacaftor estate has multiple protection layers:
- Active-ingredient and compound patents protect the underlying CFTR potentiator.
- Formulation and solid-state patents protect amorphous ivacaftor and related manufacturing methods.
- Method-of-use patents protect cystic-fibrosis treatment.
- Regulatory exclusivity delayed generic approval independently of patent rights.
- Combination products, including ivacaftor-containing CFTR modulator products, may have separate patent families and regulatory protections.
US 9,670,163 is strongest against a generic that uses a predominantly amorphous ivacaftor formulation, a polymeric solid dispersion or spray drying. It is less effective against a product that remains substantially crystalline, uses a different solid-state strategy and avoids the patented process.
The patent's value is therefore product-specific. It is not a universal block on all post-expiration ivacaftor products.
How does US 9,670,163 compare with the underlying ivacaftor patents?
| Protection type |
Typical scope |
Relevance to generic entry |
| Compound patent |
Ivacaftor chemical structure and related compounds |
Broadest chemical protection, but generally earlier expiry |
| Solid-state patent |
Amorphous or partially crystalline ivacaftor |
Directly targets physical form used in commercial formulation |
| Formulation patent |
Excipients, polymers and solid dispersions |
May reach the finished dosage form |
| Process patent |
Spray drying and related preparation steps |
Depends on the generic's manufacturing route |
| Method-of-use patent |
Treating CF with ivacaftor composition |
Depends on label language and use certification |
| Combination patent |
Ivacaftor with other CFTR modulators |
Relevant to combination products, not necessarily Kalydeco monotherapy |
The 9,670,163 patent extends protection beyond the chemical identity of ivacaftor by targeting a formulation approach designed to address solid-state and dissolution characteristics.
What generic launch scenarios exist?
Launch after patent expiry
The lowest-risk scenario is a launch after the final enforceable patent expiration, subject to FDA approval and any applicable exclusivity.
Paragraph IV launch
A generic applicant may certify that US 9,670,163 is invalid, unenforceable or not infringed. Vertex may sue within the statutory period, producing a potential 30-month approval stay.[5]
Non-infringing formulation
A generic may use a crystalline product or another solid-state form. This strategy must avoid claims 1, 6 and 7, as well as any applicable formulation patents.
Process redesign
A manufacturer may avoid claim 5 by using a non-spray-drying process. This does not avoid the composition claims if the final product still contains the claimed amorphous material.
Label carve-out
A section viii statement may remove patented uses from labeling where FDA permits the carve-out. The strategy is difficult if the product's remaining label still induces use covered by claim 3.
What manufacturing and IP barriers does the patent create?
The principal technical barrier is controlling crystallinity during manufacture, storage and distribution. Amorphous ivacaftor can recrystallize under changes in humidity, temperature, solvent activity or polymer compatibility. A generic must demonstrate:
- reproducible amorphous content;
- acceptable physical stability;
- dissolution performance;
- bioequivalence;
- batch-to-batch consistency;
- control of residual solvent;
- compatibility with excipients and packaging.
Spray drying may be commercially attractive but creates direct exposure to claim 5. A non-spray-dried process may reduce process-claim risk while increasing development risk around particle properties and solid-state stability.
What is the commercial exposure?
Kalydeco is a Vertex CF product, while ivacaftor is also incorporated into combination products such as Orkambi, Symdeko and Trikafta/Kaftrio. The revenue exposure from a generic Kalydeco launch is therefore narrower than the total commercial exposure of the broader ivacaftor franchise.[6]
A generic Kalydeco product could pressure monotherapy revenue and may create substitution pressure in eligible patients. Combination products have separate regulatory, clinical and patent considerations. A Kalydeco generic would not automatically establish substitutability for combination regimens containing ivacaftor with tezacaftor, elexacaftor or lumacaftor.
Key Takeaways
- US 9,670,163 protects amorphous ivacaftor compositions and related solid dispersions.
- Claim 1 covers amorphous ivacaftor with less than about 30% crystalline material.
- Claim 6 narrows the threshold to less than about 5% crystalline ivacaftor.
- Claim 7 targets 100% amorphous ivacaftor measured by Cu K-alpha XRPD.
- Claim 5 covers a spray-drying process beginning with crystalline ivacaftor, solvent and optional polymer.
- Claim 3 protects treatment of cystic fibrosis using the claim 1 composition.
- The reported expiration date is October 31, 2032.
- A generic using a predominantly amorphous ivacaftor formulation faces composition-claim risk even if it avoids spray drying.
- A process redesign can avoid claim 5 but may not avoid claims 1, 6, 7 or 8.
- Kalydeco's NME and orphan exclusivities are separate from the patent term and have expired or run their ordinary statutory periods.
FAQs
Does US 9,670,163 cover crystalline ivacaftor?
No. The claims require amorphous ivacaftor, although claim 1 permits less than about 30% crystalline ivacaftor and claim 6 permits less than about 5%.
Can a generic avoid US 9,670,163 by using a tablet instead of a capsule?
Not necessarily. The claims are directed to composition and solid-state characteristics, not a specific capsule dosage form. A tablet containing the claimed amorphous composition could still infringe.
Does avoiding the spray-drying process eliminate all patent risk?
No. Avoiding spray drying may address claim 5, but a final product can still implicate composition, solid-dispersion or polymer claims.
Is ivacaftor eligible for biosimilar competition?
No. Ivacaftor is a chemically synthesized small molecule, not a biologic. Competition proceeds through the ANDA generic-drug pathway rather than the biosimilar pathway.
Can XRPD testing determine whether a generic infringes claim 7?
XRPD is the claim-specified technique, but infringement analysis depends on the test protocol, detection capability, sample preparation and the interpretation of "100% amorphous" under the patent and prosecution record.
References
-
United States Patent and Trademark Office. (2017). US Patent No. 9,670,163, solid forms of ivacaftor. U.S. Department of Commerce.
-
U.S. Food and Drug Administration. (2012). FDA approves Kalydeco to treat rare form of cystic fibrosis. https://www.fda.gov
-
United States Patent and Trademark Office. (n.d.). Patent term calculator and patent term adjustment information. https://www.uspto.gov
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov
-
Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
-
Vertex Pharmaceuticals Incorporated. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.
